Antipsychotic drug use in 503 Chinese inpatients with schizophrenia

References

• Tang YL. [Pharmacotherapy of schizophrenia]. Schizophrenia: From biology to treatments (in Chinese), ZJ Cai, YZ Weng, YL Tang. The Science Press, BeijingChina 2000; 214–27 (in Chinese)
   Google Scholar
• Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004; 58(1)61–7
   PubMed Web of Science ®Google Scholar
• Potter WZ, Ko GN, Zhang LD, Yan WW. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berlin) 1989; 99(Suppl)S87–91
   PubMedGoogle Scholar
• Wu TC, Tang GR. [Clinical use of antipsychotics and follow-up study]. Chin J Neuropsychiatr 1995; 28: 217 (in Chinese)
   Google Scholar
• Xu WR, Zhao BL, Cui Q, Gao MF. [A comparative study of clozapine and chlorpromazine on schizophrenia – a double-blind study]. Chin J Nerv Ment Dis 1985; 11: 222–4 (in Chinese)
   Google Scholar
• Lin RM, Song CS, Ji ZF, Jin SL, Luo Y. [Antipsychotic use in three psychiatric hospitals]. J Clin Psychol Med 2002; 12(2)106–7 (in Chinese)
   Google Scholar
• Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50(9)329–38
   PubMed Web of Science ®Google Scholar
• Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21(6)515–23
   PubMed Web of Science ®Google Scholar
• Chen Q, Tang YL, Mao PX, Cai ZJ. [Effect of clozapine and risperidone on the glucose-regulating mechanism in schizophrenic patients]. Chin J Clin Rehab 2005; 9(4)116–8 (in Chinese)
   Google Scholar
• World Health Organization. The Asia-Pacific perspective. Redefining obesity and its treatment. International Diabetes Institute. Health Communications Australia Pty Ltd; 2000.
   Google Scholar
• Expert Committee on Abnormal Blood Lipids. [Recommendations for the prevention and treatment of abnormal blood lipid]. Chin J Cardiovasc 1997;25:169–75.
   Google Scholar
• Si T, He YL, Zhou RY, Wang XD, Shu L, Liu XH. Prescription pattern for patients with schizophrenia in three regions of China. Chin Ment Health J 2003; 10: 537–40 (in Chinese)
   Google Scholar
• Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003; 54(1)55–9
   PubMed Web of Science ®Google Scholar
• Sim K, Su A, Chan YH, Shinfuku N, Kua EH, Tan CH. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry Clin Neurosci 2004; 58(3)324–9
   PubMed Web of Science ®Google Scholar
• Bitter I, Chou JC, Ungvari GS, Tang WK, Xiang Z, Iwanami A, et al. Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry 2003; 36(4)143–9
   PubMed Web of Science ®Google Scholar
• Wilson WH, Ban TA, Guy W. Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices. Neuropsychobiology 1985; 14(2)75–82
   PubMed Web of Science ®Google Scholar
• Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53(Suppl)S35–40
   Google Scholar
• Ruiz S, Chu P, Sramek J, Rotavu E, Herrera J. Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med 1996; 63(5–6)306–9
   PubMedGoogle Scholar
• Jin Z. Effect of an open-door policy combined with a structured activity programme on the residual symptoms of schizophrenic in-patients. A six-month randomised controlled trial in Yanbian, Jilin. Br J Psychiatry 1994; 24(Suppl)52–7
   Google Scholar
• Peralta V, Cuesta MJ, Caro F, Martinez-Larrea A. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices. Acta Psychiatr Scand 1994; 90(5)354–7
   PubMed Web of Science ®Google Scholar
• Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Can J Psychiatry 1997; 42(1)53–7
   PubMed Web of Science ®Google Scholar
• Galletly CA. Antipsychotic drug doses in a schizophrenia inpatient unit. Aust NZ J Psychiatry 1992; 26(4)574–6
   PubMed Web of Science ®Google Scholar
• Zito JM, Craig TJ, Wanderling J, Siegel C. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. Am J Psychiatry 1987; 144(6)778–82
   PubMedGoogle Scholar
• Su A, Leong JY, Yip K, Chong MY, Fujii S, Yang S, et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 2004; 37(4)175–9
   PubMed Web of Science ®Google Scholar
• Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003; 29(3)531–40
   PubMed Web of Science ®Google Scholar
• Tempier RP, Pawliuk NH. Conventional, atypical, and combination antipsychotic prescriptions: A 2-year comparison. J Clin Psychiatry 2003; 64(6)673–9
   PubMed Web of Science ®Google Scholar
• Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: A pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 2000; 15(3)220–6
   PubMed Web of Science ®Google Scholar
• Citrome L, Volavka J. The promise of atypical antipsychotics–fewer side effects mean enhanced compliance and improved functioning. Postgrad Med 2004; 116(4)49–63
   PubMed Web of Science ®Google Scholar
• Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003; 2: CD000440
   Google Scholar
• Martin BC, Miller LS, Kotzan JA. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: Current trends and five year time series forecasts. Schizophr Res 2001; 47: 281–92
   PubMed Web of Science ®Google Scholar
• Mamdani MM, Tu K, Austin PC, Alter DA. Influence of socioeconomic status on drug selection for the elderly in Canada. Ann Pharmacother 2002; 36(5)804–8
   PubMed Web of Science ®Google Scholar
• Apiquian R, Fresan A, de la Fuente-Sandoval C, Ulloa RE, Nicolini H. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. BMC Psychiatry 2004; 4(1)12
   PubMedGoogle Scholar
• Chi ZM, Dai AQ, Sun L. [Analysis of Antipsychotic Use for Outpatients]. J Clin Psychol Med 2002; 12(2)109–10 (in Chinese)
   Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9)789–96
   PubMed Web of Science ®Google Scholar
• Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992; 17(Suppl)41–5
   Google Scholar
• Tang YL, Jiang ZN, Zhai YM, Wu YM. [Screening and evaluation of predictive factors among refractory schizophrenics treated with clozapine]. Chin J Psychiatry 1997; 30(3)157–61 (in Chinese)
   Google Scholar
• Kane JM, Leucht S, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003; 64(Suppl 12)1–100
   Google Scholar
• He B, Ding YQ, Wang CY. [Clozapine-induced leukopenia and agranulocytosis in China]. Evaluation Anal Drug Use Hospital China 2003; 3(5)307–11 (in Chinese)
   Google Scholar
• Hou XX, Ying ML, Zhou JD. Changes of white blood cell count among 1434 patients on clozapine. Chin J New Drugs Clin Remedies 1989; 8(4)222–4 (in Chinese)
   Google Scholar
• Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock's synopsis of psychiatry: Behavorial sciences, clinical psychiatry7th ed. Williams & Wilkins, Baltimore, MD 1994; xvi, 1257
   Google Scholar
• Yang JS, Zhang WL. [Clozapine and agranulocytosis]. Shanghai Arch Psychiatry 1990; n2(4)190–1 (in Chinese)
   Google Scholar
• Chen B, Lu MK. Analysis of 30 cases of clozapine and agranulocytosis. Shanghai Arch Pyschiatry 1997; n9(4)278–9 (in Chinese)
   Google Scholar
• Lu MK, Hou XX, Ying ML. Analysis of side effects of clozapine. Chin J Neuropyschiatry 1991; 24(2)71–4 (in Chinese)
   Google Scholar
• Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New Engl J Med 1993; 329(3)162–7
   PubMed Web of Science ®Google Scholar
• Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59(Suppl 3)3–7
   PubMed Web of Science ®Google Scholar
• Wang LW, Wang ZC. Can clozapine be used as a first-line antipsychotic drug? Shanghai Arch Pyschiatry 1999;n11(2):107–11 (in Chinese).
   Google Scholar
• Zhao HQ. Handbook of psychotropic treatment1st ed. People's Military Medical Press, BeijingChina 1998; 836 (in Chinese)
   Google Scholar
• Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002; 71(5)244–54
   PubMed Web of Science ®Google Scholar
• Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998; 155(4)499–504
   PubMed Web of Science ®Google Scholar
• Henderson DC. Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001; 62(Suppl 23)39–44
   PubMedGoogle Scholar
• Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001; 111(9)716–23
   PubMed Web of Science ®Google Scholar
• Liberty IF, Todder D, Umansky R, Harman-Boehm I. Atypical antipsychotics and diabetes mellitus: An association. Isr Med Assoc J 2004; 6(5)276–9
   PubMed Web of Science ®Google Scholar
• Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11(1)25–32
   PubMed Web of Science ®Google Scholar